CRIS Current Research Information System

FUSAROLI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.123
NA - Nord America 2.051
EU - Europa 1.501
SA - Sud America 195
Continente sconosciuto - Info sul continente non disponibili 158
AF - Africa 106
OC - Oceania 24
Totale 7.158
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.965
CN - Cina 957
SG - Singapore 797
IT - Italia 726
VN - Vietnam 517
HK - Hong Kong 255
KR - Corea 167
BR - Brasile 148
IN - India 128
DE - Germania 127
NL - Olanda 109
BD - Bangladesh 100
SE - Svezia 83
GB - Regno Unito 76
FR - Francia 67
JP - Giappone 65
FI - Finlandia 51
RU - Federazione Russa 50
CA - Canada 45
CI - Costa d'Avorio 36
IE - Irlanda 35
ID - Indonesia 32
AT - Austria 28
AR - Argentina 25
BG - Bulgaria 25
CH - Svizzera 24
ES - Italia 22
TG - Togo 21
ZA - Sudafrica 20
AU - Australia 16
TH - Thailandia 15
TR - Turchia 15
IQ - Iraq 14
PL - Polonia 14
SA - Arabia Saudita 11
GR - Grecia 10
JM - Giamaica 10
PH - Filippine 10
BE - Belgio 9
MX - Messico 9
MY - Malesia 9
PT - Portogallo 9
NZ - Nuova Zelanda 8
UA - Ucraina 8
CO - Colombia 5
JO - Giordania 5
KE - Kenya 5
LT - Lituania 5
NG - Nigeria 5
PK - Pakistan 5
SC - Seychelles 5
TW - Taiwan 5
CR - Costa Rica 4
CZ - Repubblica Ceca 4
EC - Ecuador 4
EG - Egitto 4
HU - Ungheria 4
NI - Nicaragua 4
NP - Nepal 4
PE - Perù 4
RS - Serbia 4
BA - Bosnia-Erzegovina 3
CL - Cile 3
GH - Ghana 3
GT - Guatemala 3
MA - Marocco 3
VE - Venezuela 3
HN - Honduras 2
IL - Israele 2
KZ - Kazakistan 2
OM - Oman 2
PR - Porto Rico 2
PY - Paraguay 2
SI - Slovenia 2
SV - El Salvador 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
BJ - Benin 1
BM - Bermuda 1
BY - Bielorussia 1
DK - Danimarca 1
DM - Dominica 1
ET - Etiopia 1
GP - Guadalupe 1
HR - Croazia 1
HT - Haiti 1
KN - Saint Kitts e Nevis 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MT - Malta 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
UZ - Uzbekistan 1
XK - ???statistics.table.value.countryCode.XK??? 1
YE - Yemen 1
Totale 7.001
Salva come PNG Salva come JPEG
Città #
Singapore 562
Hefei 400
Ashburn 271
Hong Kong 239
Bologna 211
San Jose 208
Seoul 162
Ho Chi Minh City 144
Hanoi 132
Council Bluffs 122
Santa Clara 101
Boardman 81
Chandler 74
Los Angeles 70
Beijing 66
Milan 60
Tokyo 50
The Dalles 45
Dallas 44
Lauterbourg 38
Bengaluru 37
Abidjan 36
New York 36
Dublin 34
Helsinki 34
Rome 32
Princeton 28
Jakarta 26
Buffalo 25
Redmond 24
Sofia 24
Southend 24
Da Nang 23
Haiphong 21
Lomé 21
Redondo Beach 21
Orem 20
Shanghai 20
São Paulo 20
Bern 19
Frankfurt am Main 19
Modena 19
Vienna 18
Atlanta 15
Biên Hòa 15
Munich 15
Chicago 14
Turin 14
Florence 13
Guangzhou 13
Amsterdam 12
Fairfield 12
Houston 12
Johannesburg 12
London 12
Nuremberg 12
Phoenix 12
Tongling 12
Toronto 12
Cesena 10
Naples 10
Rimini 10
Bangkok 9
Hangzhou 9
Lappeenranta 9
Montreal 9
San Diego 9
Seattle 9
Indianapolis 8
Monselice 8
Nha Trang 8
Paris 8
Poplar 8
San Francisco 8
Shenzhen 8
Suzhou 8
Xi'an 8
Brooklyn 7
Brussels 7
Can Tho 7
Chengdu 7
Denver 7
Genoa 7
Hyderabad 7
New Delhi 7
Ninh Bình 7
Auckland 6
Berlin 6
Brescia 6
Bến Tre 6
Cambridge 6
City of London 6
Dundee 6
Embrun 6
Hải Dương 6
Jinan 6
Lizzano 6
Mercato Saraceno 6
Mexico City 6
Milwaukee 6
Totale 4.171
Salva come PNG Salva come JPEG
Nome #
Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions 319
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the ‘impulse control disorders’ diagnostic construct 293
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System 241
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System 239
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study 235
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 219
Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry 217
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems 207
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System 203
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors 203
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS 202
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment 192
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement 185
Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People 183
Assessing the environmental impact of medicines in Italy using data from the Italian Medicines Agency 179
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies 171
Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase 171
The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration 166
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System 162
Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System 147
The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline 145
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians 143
Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System 141
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19 138
Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database 126
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System 122
Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list 122
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System 122
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System 120
Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study 116
Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase® Spontaneous Reporting System 114
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System 114
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis 112
What Is the Safety Profile of Cannabis-Based Medications? Analysis of the Post-Marketing Signals from the FDA Adverse Event Reporting System 111
Post-marketing safety profile of cannabis products: Signals from the FDA adverse event reporting system 109
Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal 105
The evolving role of disproportionality analysis in pharmacovigilance 96
Environmental sustainability-an essential component of rational use of medicines 91
Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance 91
Characterizing post-mortem blood concentrations in methadone-related deaths 81
Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database 81
Meta-analyzing Results From Disproportionality Analysis of Individual Case Safety Reports A Note of Caution 81
Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting System 80
Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system 80
Authors’ Reply to Robert P. Giugliano and Colleagues’ Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance” 75
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach 72
Ivabradine, atrial fibrillation and stroke: a combined meta-analysis and FAERS disproportionality analysis 69
Are Causal Statements Reported in Pharmacovigilance Disproportionality Analyses Using Individual Case Safety Reports Exaggerated in Related Citations? A Meta-epidemiological Study 54
Interpretation of Pharmacovigilance Disproportionality Analyses 49
Real-world evidence and pharmacovigilance: workshop of the Italian Epidemiological Association and of the Italian Society of Pharmacology 36
Transparency and robustness of safety signals 28
Totale 7.158
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.743
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.743
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022255 0 0 7 10 10 10 36 47 20 21 58 36
2022/2023478 36 19 31 32 48 38 45 48 81 14 54 32
2023/2024420 36 41 41 56 43 60 22 39 15 30 30 7
2024/20251.651 93 139 165 104 129 66 109 129 65 119 175 358
2025/20264.000 406 508 340 301 330 153 586 184 477 243 205 267
2026/2027317 183 134 0 0 0 0 0 0 0 0 0 0
Totale 7.158